Our objective is to develop and bring to market the most advanced therapies for patients suffering from severe rare genetic skin diseases. These therapies are based on the transformative potential of single-course antenatal protein-replacement and SNA genetic therapeutic approaches. In order to accomplish our mission, it is of the utmost importance that we fully understand and consider, on an ongoing basis, the needs and preferences of the patient communities we serve.

We are committed to our vision of turning hope into reality for patients with rare genetic skin diseases.

If you are interested in learning more about our activities within the patient community, please contact patientadvocacy@dermelix.com. By providing your information you agree to allow Dermelix to collect the name and email address provided and to be contacted by Dermelix and its partners using this information.